The Task Force sought to improve the employment of MRI’s capabilities in the treatment of epilepsy, which the authors noted “are variable worldwide and may not harness the full potential of recent technological advances for the benefit of people with epilepsy.”
Does the clinical picture point to a reaction to alcohol? A food allergy? What do you suspect is the likely culprit?
The efficacy of CBT using the American Academy of Sleep Medicine (AASM) SleepTM platform has been shown to be similarly efficacious to face-to-face physician encounters in 30 adults with chronic insomnia.
A significant risk for cognitive impairment was observed in adults with short sleep duration and cardiometabolic risk factors, such as hypertension or diabetes.
Neurology News Network for the week ending June 8, 2019.
The FDA has approved an sBLA for deflazacort that expands the label to patients aged 2 to 5 with Duchenne muscular dystrophy.
